A high level of PD-L1 also suggests the potential use of immunotherapy involving checkpoint inhibitors, such as PD-1/PD-L1 blocking antibodies, which opens new therapeutic possibilities for patients with advanced cancers [134,135]. This evidence concerns the gene CD274 and cancer.